In an adult with type 2 diabetes or obesity, how does retatrutide (a GLP‑1, GIP, and glucagon‑receptor agonist) modulate glucagon secretion?

Retatrutide Modulates Glucagon Secretion Through Direct Glucagon Receptor Agonism

Retatrutide does not suppress glucagon secretion like traditional GLP-1 agonists; instead, it directly stimulates glucagon receptors as part of its triple-agonist mechanism, while simultaneously activating GLP-1 and GIP receptors to achieve superior weight loss and glycemic control. 1

Mechanism of Action

Retatrutide functions as a tri-agonist targeting three distinct receptor systems 1:

• GLP-1 receptor agonism: Enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release in hyperglycemic states
• GIP receptor agonism: Potentiates insulin secretion and modulates metabolic pathways
• Glucagon receptor agonism: Directly stimulates glucagon receptors to increase energy expenditure

This represents a paradigm shift from traditional incretin-based therapies. While conventional GLP-1 receptor agonists work by suppressing glucagon secretion during hyperglycemia, retatrutide paradoxically activates glucagon receptors 2, 3, 4.

The Glucagon Component: From Antagonist to Agonist

The inclusion of glucagon receptor agonism is counterintuitive but mechanistically sound 4:

• Energy expenditure: Glucagon receptor activation increases metabolic rate and promotes fat oxidation, contributing to the exceptional 24% weight loss observed at 48 weeks 1
• Hepatic effects: Stimulates hepatic glucose output and fatty acid oxidation
• Thermogenesis: Enhances energy expenditure independent of food intake reduction 3, 4

Preclinical evidence demonstrates that GIPR:GCGR co-agonism can reverse obesity even in GLP-1 receptor knockout mice, proving that glucagon receptor activation contributes meaningfully to weight reduction without requiring GLP-1 activity 3.

Clinical Implications for Glucagon Dynamics

In the TRANSCEND-T2D-1 trial, retatrutide achieved HbA1c reductions of 1.69-1.94% despite activating glucagon receptors 5. This occurs because:

1. Glucose-dependent effects: The GLP-1 component ensures insulin secretion is enhanced when glucose is elevated, counterbalancing any hyperglycemic effects from glucagon receptor stimulation
2. Balanced receptor activation: The tri-agonist design creates a net beneficial metabolic state where increased energy expenditure from glucagon receptor activation outweighs potential glucose-raising effects
3. Weight loss benefits: The 11.5-15.3% weight reduction at 40 weeks 5 improves insulin sensitivity, which helps maintain glycemic control despite glucagon receptor stimulation

Important Caveats

• Not traditional glucagon suppression: Clinicians accustomed to GLP-1 monotherapy should understand that retatrutide does not work by suppressing glucagon; it actively stimulates glucagon receptors 2, 4
• Mechanism still being defined: The precise role of glucagon receptor agonism in humans remains incompletely characterized, with most mechanistic data derived from rodent models 2, 4
• Safety profile: The glucagon component does not appear to increase hypoglycemia risk, with no severe hypoglycemia reported in phase 3 trials 5

Comparison to Other Agents

Unlike tirzepatide (GLP-1/GIP dual agonist) which achieved 21% weight loss at 72 weeks 1, retatrutide's addition of glucagon receptor agonism pushes weight loss to 24% at 48 weeks 1. The glucagon component specifically contributes to this enhanced efficacy through increased energy expenditure rather than appetite suppression alone 3, 4.

The gastrointestinal adverse events (nausea, vomiting) remain similar to other GLP-1-containing agents, with 2-5% discontinuation rates 5, suggesting the glucagon component does not substantially worsen tolerability.